| Name | Title | Contact Details |
|---|
Diabetes Health Net is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. Today we have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. Our Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare. As medicine moves from major surgery to minor procedure, no company endeavours to do more to help doctors in their quest to see more, reach further and treat smarter. We understand their needs and equip them with tools and techniques that would have seemed like science fiction only a generation ago. We invest in clinical evidence that helps demonstrate the value of our treatments to patients, doctors, and healthcare systems. With relentless curiosity we`ll work with clinicians to find elegant new ways to extend our power over disease and transform patient care. There are no limits to where our ideas will take us.
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the complete product lifecycle through an advise-build-operate model. Our end-to-end suite of consulting solutions de-risk and accelerate high-profile drug and device programs, ultimately improving patient health and safety. Discover how ProPharma can help you inspire the future of science!
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
County Of Ripley is a Doniphan, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.